Paolo Moghetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9072648/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 139-146.	3.6	582
2	Estimates of <i>In Vivo</i> Insulin Action in Man: Comparison of Insulin Tolerance Tests with Euglycemic and Hyperglycemic Glucose Clamp Studies*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 374-378.	3.6	508
3	Metformin Effects on Clinical Features, Endocrine and Metabolic Profiles, and Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled 6-Month Trial, followed by Open, Long-Term Clinical Evaluation. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 139-146.	3.6	437
4	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2012, 18, 146-170.	10.8	367
5	Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial). Hepatology, 2013, 58, 1287-1295.	7.3	275
6	Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care, 2000, 23, 45-50.	8.6	235
7	The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women Journal of Clinical Endocrinology and Metabolism, 1996, 81, 952-960.	3.6	191
8	Divergences in Insulin Resistance Between the Different Phenotypes of the Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E628-E637.	3.6	186
9	Metabolic Effects of Aerobic Training and Resistance Training in Type 2 Diabetic Subjects. Diabetes Care, 2012, 35, 676-682.	8.6	177
10	Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 89-94.	3.6	164
11	Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity Journal of Clinical Endocrinology and Metabolism, 1996, 81, 881-886.	3.6	154
12	Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 89-94.	3.6	153
13	The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 952-960.	3.6	151
14	Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia, 1995, 38, 1122-1124.	6.3	150
15	The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia, 1995, 38, 318-325.	6.3	139
16	Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 881-886.	3.6	134
17	Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 543-549.	2.6	130
18	Insulin resistance and PCOS: chicken or egg?. Journal of Endocrinological Investigation, 2021, 44, 233-244.	3.3	99

#	Article	IF	CITATIONS
19	Insulin Resistance and Polycystic Ovary Syndrome. Current Pharmaceutical Design, 2016, 22, 5526-5534.	1.9	93
20	The Methionine 196 Arginine Polymorphism in Exon 6 of the TNF Receptor 2 Gene (TNFRSF1B) Is Associated with the Polycystic Ovary Syndrome and Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3977-3983.	3.6	92
21	Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Human Reproduction, 2017, 32, 2515-2521.	0.9	90
22	Insulin Sensitivity, Binding, and Kinetics in Pancreatogenic and Type I Diabetes. Diabetes, 1982, 31, 346-355.	0.6	81
23	Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertility and Sterility, 1996, 66, 734-740.	1.0	77
24	Insulin Resistance and the Persistence of Obesity from Childhood into Adulthood. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 71-76.	3.6	76
25	Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clinical Endocrinology, 1998, 48, 169-173.	2.4	74
26	Metabolic Effects of Exercise. Frontiers of Hormone Research, 2016, 47, 44-57.	1.0	73
27	Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertility and Sterility, 1995, 64, 511-517.	1.0	72
28	Hyperinsulinemia Amplifies GnRH Agonist Stimulated Ovarian Steroid Secretion in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1712-1719.	3.6	67
29	A Study of the Hexose-6-Phosphate Dehydrogenase Gene R453Q and 11β-Hydroxysteroid Dehydrogenase Type 1 Gene 83557insA Polymorphisms in the Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4157-4162.	3.6	63
30	Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia, 1995, 38, 672-679.	6.3	61
31	Treatment of polycystic ovary syndrome with spironolactone plus licorice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2007, 131, 61-67.	1.1	61
32	Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clinical Endocrinology, 2008, 68, 481-484.	2.4	60
33	Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1115-1121.	3.6	58
34	Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism Journal of Clinical Endocrinology and Metabolism, 1994, 79, 1115-1121.	3.6	56
35	Total Body Fat and Central Fat Mass Independently Predict Insulin Resistance but Not Hyperandrogenemia In Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 661-669.	3.6	54
36	Treatment of hirsutism and acne in hyperandrogenism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 221-234.	4.7	51

#	Article	IF	CITATIONS
37	Ten-week Whole-body Vibration Training Improves Body Composition and Muscle Strength in Obese Women. International Journal of Medical Sciences, 2013, 10, 307-311.	2.5	51
38	Implications of Androgen Assay Accuracy in the Phenotyping of Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 610-618.	3.6	51
39	Effect of moderate aerobic exercise on sympatho-vagal balance in Type 2 diabetic patients. Diabetic Medicine, 2007, 24, 370-376.	2.3	50
40	Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertility and Sterility, 2003, 79, 219-220.	1.0	49
41	Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. European Journal of Endocrinology, 2009, 161, 737-745.	3.7	48
42	Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism: Clinical and Experimental, 2003, 52, 862-867.	3.4	46
43	Disorders of Coagulation and Hemostasis in Abdominal Obesity: Emerging Role of Fatty Liver. Seminars in Thrombosis and Hemostasis, 2010, 36, 041-048.	2.7	46
44	Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. European Journal of Endocrinology, 2011, 164, 197-203.	3.7	44
45	Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads Journal of Clinical Endocrinology and Metabolism, 1995, 80, 836-840.	3.6	41
46	Power spectral analysis of heart rate in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2828-2835.	3.6	41
47	Chromosome Translocation Frequency after Radioiodine Thyroid Remnant Ablation: A Comparison between Recombinant Human Thyrotropin Stimulation and Prolonged Levothyroxine Withdrawal. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3472-3476.	3.6	40
48	Power spectral analysis of heart rate in hypothyroidism. European Journal of Endocrinology, 2000, 143, 327-333.	3.7	39
49	Differences in the Acute Effects of Aerobic and Resistance Exercise in Subjects with Type 2 Diabetes: Results from the RAED2 Randomized Trial. PLoS ONE, 2012, 7, e49937.	2.5	39
50	Supervised Walking Groups to Increase Physical Activity in Type 2 Diabetic Patients. Diabetes Care, 2010, 33, 2333-2335.	8.6	38
51	Sustained therapy with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors does not impair steroidogenesis by adrenals and gonads. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 836-840.	3.6	38
52	Acute Effect of Insulin on Autonomic Regulation of the Cardiovascular System: A Study by Heart Rate Spectral Analysis. Diabetic Medicine, 1996, 13, 709-714.	2.3	37
53	Spironolactone, But Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1250-1254.	3.6	36
54	Metabolic Inflexibility Is a Feature of Women With Polycystic Ovary Syndrome and Is Associated With Both Insulin Resistance and Hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2581-2588.	3.6	36

Ραοιο Μοghetti

#	Article	IF	CITATIONS
55	Influence of Body Fat and its Regional Localization on Risk Factors for Atherosclerosis in Young Men. American Journal of Epidemiology, 1992, 135, 1271-1278.	3.4	33
56	Reassessing Free-Testosterone Calculation by Liquid Chromatography–Tandem Mass Spectrometry Direct Equilibrium Dialysis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2167-2174.	3.6	33
57	Leptin concentration in newborns' cord blood: relationship to gender and growth-regulating hormones. International Journal of Obesity, 1999, 23, 943-947.	3.4	32
58	Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 2009, 32, 695-700.	3.3	32
59	Walking for subjects with type 2 diabetes: A systematic review and joint AMD/SID/SISMES evidence-based practical guideline. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1882-1898.	2.6	32
60	Physical Activity Patterns in Normal-Weight and Overweight/Obese Pregnant Women. PLoS ONE, 2016, 11, e0166254.	2.5	31
61	Antiandrogen Drugs Lower Serum Prostate-Specific Antigen (PSA) Levels in Hirsute Subjects: Evidence That Serum PSA Is a Marker of Androgen Action in Women. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 81-84.	3.6	30
62	Effects of aerobic or resistance exercise training on cardiovascular autonomic function of subjects with type 2 diabetes: A pilot study. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 226-233.	2.6	26
63	Insulin Receptor on Monocytes from Patients with Acromegaly and Fasting Hyperglycemia*. Journal of Clinical Endocrinology and Metabolism, 1983, 56, 733-738.	3.6	23
64	Clustering of Cardiovascular Risk Factors Associated With the Insulin Resistance Syndrome: Assessment by principal component analysis in young hyperandrogenic women. Diabetes Care, 2006, 29, 372-378.	8.6	23
65	Effects of Aerobic and Resistance Training on Circulating Micro-RNA Expression Profile in Subjects With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1119-1130.	3.6	23
66	The free androgen index is inaccurate in women when the SHBG concentration is low. Clinical Endocrinology, 2018, 88, 706-710.	2.4	22
67	Managing Erectile Dysfunction in Heart Failure. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2013, 13, 125-134.	1.2	21
68	Early changes in plasma glucagon and growth hormone response to oral glucose in experimental hyperthyroidism. Metabolism: Clinical and Experimental, 1996, 45, 1029-1033.	3.4	20
69	Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome. European Journal of Endocrinology, 2014, 170, 401-409.	3.7	20
70	Spironolactone, But Not Flutamide, Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1250-1254.	3.6	20
71	Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. Diabetes, 1982, 31, 346-355.	0.6	20
72	Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome. Seminars in Thrombosis and Hemostasis, 2014, 40, 600-618.	2.7	18

5

#	Article	IF	CITATIONS
73	How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. Journal of Endocrinological Investigation, 2015, 38, 1025-1037.	3.3	18
74	Comparison between dual-energy X-ray absorptiometry and skinfold thickness in assessing body fat in overweigh/obese adult patients with type-2 diabetes. Scientific Reports, 2017, 7, 17424.	3.3	17
75	Glucose counterregulatory response to acute hypoglycemia in hyperthyroid human subjects. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 169-173.	3.6	15
76	Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog. European Journal of Endocrinology, 2007, 156, 99-103.	3.7	14
77	Serum Androgens Are Independent Predictors of Insulin Clearance but Not of Insulin Secretion in Women With PCOS. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1981-e1989.	3.6	14
78	Mononuclear Leukocytes from Obese Patients with Type II Diabetes have Reduced Activity of Hexokinase, 6-Phosphofructokinase and Glucose-6-Phosphate Dehydrogenase. Hormone and Metabolic Research, 1993, 25, 160-164.	1.5	13
79	Glucose counterregulatory response to acute hypoglycemia in hyperthyroid human subjects Journal of Clinical Endocrinology and Metabolism, 1994, 78, 169-173.	3.6	13
80	ls cardiorespiratory fitness impaired in PCOS women? A review of the literature. Journal of Endocrinological Investigation, 2017, 40, 463-469.	3.3	13
81	Relationships between cardiorespiratory fitness, metabolic control, and fat distribution in type 2 diabetes subjects. Acta Diabetologica, 2014, 51, 369-375.	2.5	12
82	Insulin-Mediated Substrate Use in Women With Different Phenotypes of PCOS: the Role of Androgens. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3414-e3425.	3.6	12
83	Detection of mutations in insulin receptor gene by denaturing gradient gel electrophoresis. Diabetes, 1992, 41, 408-415.	0.6	11
84	Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects. Journal of Endocrinological Investigation, 1987, 10, 311-319.	3.3	10
85	Plasma Concentrations of Growth Hormone during Hyperglycemic Clamp with or without Somatostatin Infusion in Obese Subjects*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1732-1734.	3.6	10
86	Role of Exercise in Vascular Function and Inflammatory Profile in Age-Related Obesity. Journal of Immunology Research, 2018, 2018, 1-9.	2.2	10
87	Diabetic pregnancy outcomes in mothers treated with basal insulin lispro protamine suspension or NPH insulin: a multicenter retrospective Italian study. Journal of Maternal-Fetal and Neonatal Medicine, 2016, 29, 1061-1065.	1.5	9
88	Clinical Value of Serum Levels of 11-Oxygenated Metabolites of Testosterone in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2047-e2055.	3.6	9
89	Studies on the mechanism of action of sulphonylureas in type II diabetic subjects: gliquidone. Journal of Endocrinological Investigation, 1992, 15, 1-11.	3.3	8
90	Insulin resistance: what is its role in the polycystic ovary syndrome?. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 444-450.	0.6	8

Paolo Moghetti

#	Article	IF	CITATIONS
91	Use of antiandrogens as therapy for women with polycystic ovary syndrome. Fertility and Sterility, 2006, 86, S30-S31.	1.0	8
92	Low body weight and menstrual dysfunction are common findings in both elite and amateur ballet dancers. Journal of Endocrinological Investigation, 2013, 36, 343-6.	3.3	8
93	Glucose and insulin suppression of plasma free fatty acids in obese subjects with normal glucose tolerance or mild, newly diagnosed Type 2 (non-insulin-dependent) diabetes. Journal of Endocrinological Investigation, 1990, 13, 55-59.	3.3	7
94	The M235T polymorphism of the angiotensinogen gene in women with polycystic ovary syndrome. Fertility and Sterility, 2005, 84, 1520-1521.	1.0	7
95	Serum testosterone predicts cardiorespiratory fitness impairment in normalâ€weight women with polycystic ovary syndrome. Clinical Endocrinology, 2015, 83, 895-901.	2.4	7
96	Sex differences in the association of psychological status with measures of physical activity and sedentary behaviour in adults with type 2 diabetes. Acta Diabetologica, 2018, 55, 627-635.	2.5	7
97	Current treatment for polycystic ovary syndrome: focus on adolescence. Minerva Pediatrica, 2020, 72, 288-311.	2.7	7
98	Plasma concentrations of glucagon during hyperglycemic clamp with or without somatostatin infusion in obese subjects. Acta Diabetologica Latina, 1990, 27, 309-314.	0.2	6
99	Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human Reproduction Update, 2013, 19, 207-207.	10.8	6
100	Exercise for Hepatic Fat Accumulation in Type 2 Diabetic Subjects. International Journal of Endocrinology, 2013, 2013, 1-5.	1.5	6
101	A Case Report of Insulinoma Relapse on Background Nesidioblastosis: A Rare Cause of Adult Hypoglycemia. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 773-778.	3.6	6
102	Enzymatic Activities Related to Intermediary Metabolism of Glucose in Circulating Mononuclear Cells from Obese Humans: Relationship to Enzyme Activity in Adipose Tissue. Enzyme, 1990, 43, 26-32.	0.7	5
103	Plasma C-peptide response to oral glucose load in hyperthyroidism. Journal of Endocrinological Investigation, 1990, 13, 555-557.	3.3	5
104	Association of free-living physical activity measures with metabolic phenotypes in type 2 diabetes at the time of diagnosis. The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS). Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 343-351.	2.6	5
105	Differences in glucose metabolic enzyme activities in human adipose tissue from abdominal and gluteal regions. Metabolism: Clinical and Experimental, 1988, 37, 820-823.	3.4	4
106	Normal Inhibition by Somatostatin of Glucose-Stimulated B Cell Secretion in Obese Subjects. Hormone and Metabolic Research, 1990, 22, 584-588.	1.5	4
107	Fasting plasma glucose and diabetes diagnosis. Clinica Chimica Acta, 1996, 252, 209-213.	1.1	4
108	Advances in the treatment of polycystic ovary syndrome. Expert Opinion on Investigational Drugs, 2001, 10, 1631-1640.	4.1	4

7

ΡΑΟΙΟ ΜΟGΗΕΤΤΙ

#	Article	IF	CITATIONS
109	Use of Insulin Lispro Protamine Suspension in Pregnancy. Advances in Therapy, 2015, 32, 888-905.	2.9	4
110	Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia, 1995, 38, 672-679.	6.3	4
111	New routes in the polycystic ovary syndrome labyrinth: A way out?. Journal of Endocrinological Investigation, 1998, 21, 648-655.	3.3	3
112	Comparison of plasma lipids changes after middle-distance running in euglycemic and diabetic subjects. Journal of Public Health and Emergency, 0, 3, 10-10.	4.4	3
113	VO2/PO Relationship In Type 2 Diabetic Subjects Medicine and Science in Sports and Exercise, 2016, 48, 607.	0.4	3
114	Effect of aging on growth hormone, ACTH and cortisol response to insulin-induced hypoglycemia in type I diabetes. Acta Diabetologica Latina, 1985, 22, 159-168.	0.2	2
115	Anti-TPO and anti-thyroglobulin antibodies or anti-TPO antibodies alone?. Clinical Endocrinology, 1997, 46, 235-236.	2.4	2
116	Middle-distance running and DNA damage in diabetics. Journal of Laboratory and Precision Medicine, 0, 3, 18-18.	1.1	2
117	Onset of Addison Disease appeared during the first trimester of a twin pregnancy: A case report. Clinical Case Reports (discontinued), 2021, 9, e03784.	0.5	2
118	Ovarian Suppression and Treatment of Hirsutism. , 2006, , 377-387.		2
119	For what reasons should metformin be used in the management of polycystic ovary syndrome?. Journal of Endocrinological Investigation, 2012, 35, 87-9.	3.3	2
120	Sorting the wheat from the chaff in macroprolactinaemia assessment. Annals of Clinical Biochemistry, 2006, 43, 89-89.	1.6	1
121	Polycystic ovary syndrome as a diabetes risk factor. Expert Review of Endocrinology and Metabolism, 2013, 8, 485-487.	2.4	1
122	Metabolic effect of breaks in sedentary time in subjects with type 2 diabetes. Current Opinion in Endocrine and Metabolic Research, 2019, 9, 40-44.	1.4	1
123	Monitoring exercise intensity in diabetes: applicability of "heart rate-index―to estimate oxygen consumption during aerobic and resistance training. Journal of Endocrinological Investigation, 2020, 43, 623-630.	3.3	1
124	Walking for subjects with type 2 diabetes: a systematic review and joint AMD/SID/SISMES evidence-based practical guideline. Sport Sciences for Health, 2021, 17, 1-20.	1.3	1
125	Nuove prospettive terapeutiche della sindrome dell'ovaio policistico. L Endocrinologo, 2001, 2, 8-17.	0.0	0
126	Terapia della sindrome dell'ovaio policistico. L Endocrinologo, 2003, 4, 131-142.	0.0	0

#	Article	IF	CITATIONS
127	Reply. Hepatology, 2014, 59, 352-352.	7.3	Ο
128	Glycemic Response To Acute Exercise In Type Ii Diabetes. Medicine and Science in Sports and Exercise, 2015, 47, 754.	0.4	0
129	Diabetes Secondary to Endocrine Disorders and PCOS. Endocrinology, 2018, , 1-19.	0.1	0
130	Response to Comment on Olioso D, et al. "Effect of Aerobic and Resistance Training on Circulating Micro-RNA Expression Profile in Subjects with Type 2 Diabetes― Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1930-e1931.	3.6	0
131	Circulating HMGB1 Levels Are Associated With Glucose Clamp-Derived Measures of Insulin Resistance in Women With PCOS. Journal of the Endocrine Society, 2021, 5, A738-A739.	0.2	0
132	Clinical and Hormonal Effects of the 5 alpha-Reductase Inhibitor Finasteride in Idiopathic Hirsutism. Obstetrical and Gynecological Survey, 1995, 50, 290-293.	0.4	0
133	Outcome of Long-Term Treatment With the 5 alpha-Reductase Inhibitor Finasteride in Idiopathic Hirsutism. Obstetrical and Gynecological Survey, 1997, 52, 182-184.	0.4	0
134	Authors' Response: Spironolactone But Not Flutamide Administration Prevents Bone Loss in Hyperandrogenic Women Treated with Gonadotropin-Releasing Hormone Agonist. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4747b-4747.	3.6	0
135	PCOS and Muscle Strength. Medicine and Science in Sports and Exercise, 2016, 48, 397.	0.4	0
136	Diabetes Secondary to Endocrine Disorders and PCOS. Endocrinology, 2018, , 575-593.	0.1	0
137	Effects of Aerobic and Resistance Training on Circulating Micro-RNA Expression Profile in Subjects with Type 2 Diabetes. Diabetes, 2018, 67, 1718-P.	0.6	0
138	Diabetes Secondary to Endocrine Disorders and PCOS. Endocrinology, 2020, , 575-593.	0.1	0
139	The multifarious role of insulin in PCOS: From pathophysiology to therapeutic management. , 2022, , 39-54.		0